BOSTON - The Massachusetts federal judge overseeing multidistrict litigation involving the antidepressant drug brands Celexa and Lexapro on Aug. 8 granted summary judgment to the manufacturer of Celexa on a California man's claims that the company violated that state's unfair competition law (UCL) by misrepresenting that the drug was safe and effective for minor children (In re: Celexa and Lexapro marketing and sales practices litigation, MDL No. 09-2067; [Scott A. Wilcox v. Forest Pharmaceuticals, Inc. and Forest Laboratories, Inc., No. 10-10154, D. Mass.; 2014 U.S. Dist. LEXIS 109667]).